Public Policy
Clinical Pharmacology & Therapeutics (2007) 82, 228–230. doi:10.1038/sj.clpt.6100238; published online 30 May 2007
Regulatory Considerations for Determining Postmarketing Study Commitments
R J Meyer1
1FDA, Office of Drug Evaluation II, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA
Correspondence: RJ Meyer, (robert.meyer@fda.hhs.gov)
